Morgan Stanley’s Enliven Therapeutics ELVN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $5.11M | Buy |
254,848
+173,533
| +213% | +$3.48M | ﹤0.01% | 4047 |
|
|
2025
Q1 | $1.6M | Sell |
81,315
-29,291
| -26% | -$576K | ﹤0.01% | 4746 |
|
|
2024
Q4 | $2.49M | Sell |
110,606
-24,801
| -18% | -$558K | ﹤0.01% | 4558 |
|
|
2024
Q3 | $3.46M | Buy |
135,407
+67,107
| +98% | +$1.71M | ﹤0.01% | 4245 |
|
|
2024
Q2 | $1.6M | Buy |
68,300
+5,203
| +8% | +$122K | ﹤0.01% | 4690 |
|
|
2024
Q1 | $1.11M | Sell |
63,097
-95,945
| -60% | -$1.69M | ﹤0.01% | 4900 |
|
|
2023
Q4 | $2.2M | Buy |
159,042
+125,072
| +368% | +$1.73M | ﹤0.01% | 4872 |
|
|
2023
Q3 | $464K | Buy |
33,970
+649
| +2% | +$8.87K | ﹤0.01% | 5199 |
|
|
2023
Q2 | $680K | Buy |
33,321
+15,903
| +91% | +$325K | ﹤0.01% | 5053 |
|
|
2023
Q1 | $381K | Buy |
17,418
+3,231
| +23% | +$70.8K | ﹤0.01% | 5407 |
|
|
2022
Q4 | $232K | Sell |
14,187
-1,129
| -7% | -$18.5K | ﹤0.01% | 5604 |
|
|
2022
Q3 | $140K | Sell |
15,316
-7,708
| -33% | -$70.5K | ﹤0.01% | 5904 |
|
|
2022
Q2 | $112K | Sell |
23,024
-2,460
| -10% | -$12K | ﹤0.01% | 6213 |
|
|
2022
Q1 | $191K | Sell |
25,484
-57,211
| -69% | -$429K | ﹤0.01% | 5948 |
|
|
2021
Q4 | $744K | Buy |
82,695
+10,033
| +14% | +$90.3K | ﹤0.01% | 5288 |
|
|
2021
Q3 | $1.19M | Sell |
72,662
-34,596
| -32% | -$565K | ﹤0.01% | 4943 |
|
|
2021
Q2 | $3.39M | Buy |
107,258
+26,676
| +33% | +$843K | ﹤0.01% | 4172 |
|
|
2021
Q1 | $2.72M | Buy |
80,582
+78,531
| +3,829% | +$2.65M | ﹤0.01% | 4010 |
|
|
2020
Q4 | $181K | Buy |
2,051
+1,815
| +769% | +$160K | ﹤0.01% | 5642 |
|
|
2020
Q3 | $19K | Sell |
236
-1,006
| -81% | -$81K | ﹤0.01% | 6087 |
|
|
2020
Q2 | $136K | Sell |
1,242
-34,847
| -97% | -$3.82M | ﹤0.01% | 5250 |
|
|
2020
Q1 | $2.31M | Buy |
+36,089
| New | +$2.31M | ﹤0.01% | 3236 |
|